Agilent Technologies, Inc.

“Agilent Technologies, Inc. ("we," "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.”

“Following this re-organization, we have three business segments - Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets, each of which comprises a reportable segment.”

“Our customers include pharmaceutical companies, laboratories, universities, healthcare providers, government agencies and public and private research institutions.”

“Applied Markets - Key End Markets The Chemicals and Advanced Materials Market.”

“we saw strong revenue growth in the pharmaceutical market led by revenue from our contract development and manufacturing organization, liquid chromatography and liquid chromatography mass spectrometry businesses”

“We deploy a multi-channel approach, marketing products to our customers through direct sales, electronic commerce, resellers, manufacturers' representatives and distributors.”

“Our products fall into the following main areas of work: gas chromatography, mass spectrometry, spectroscopy, vacuum technology and remarketed instruments.”

“Most of the portfolio is vendor neutral, meaning we can serve and supply customers regardless of their instrument purchase choices.”

“revenue increased 4 percent in the Americas with a 1 percentage point unfavorable currency impact, increased 9 percent in Europe with a 2 percentage point favorable currency impact and increased 5 percent in Asia Pacific with a 1 percentage point unfavorable currency impact”

“We anticipate that revenue from international operations will continue to represent a majority of our total revenue.”

“Products$4,944 $4,672 $5,051 6%(7)% Services and other$2,004 $1,838 $1,782 9%3% Total net revenue$6,948 $6,510 $6,833 7%(5)%”

“Life Sciences and Diagnostics Markets$2,726 $2,466 $2,780 11%(11)% Agilent CrossLab$2,908 $2,747 $2,656 6%3% Applied Markets$1,314 $1,297 $1,397 1%(7)% Total net revenue$6,948 $6,510 $6,833 7%(5)%”

“Agilent's net revenue of $6,948 million in 2025 increased 7 percent when compared to 2024.”

“Our hedging programs reduce, but do not always entirely eliminate the impact of currency exchange rate movements within any given twelve-month period.”

“Our hedging program is designed to hedge currency movements on a relatively short-term basis (up to a rolling twelve-month period).”

“Inside the U.S., we have a manufacturing facility in Delaware. Outside of the U.S., we have manufacturing facilities in Australia, China, Italy, Malaysia, and Singapore.”

“we outsource significant portions of our information technology and other administrative functions”

“Most of our accounting and tax processes including general accounting, cost accounting, accounts payable, accounts receivable and tax functions are centralized at locations in India and Malaysia.”

“The plan includes a reduction of our total headcount by approximately 500 regular employees, representing approximately 3 percent of our global workforce.”

“The plan included a reduction of our total headcount by approximately 400 regular employees, representing approximately 2 percent of our global workforce, and the consolidation of our excess facilities, including some site closures.”

“Revenue from our BIOVECTRA acquisition contributed approximately 2 percentage points in 2025.”

“Revenue from our BIOVECTRA acquisition contributed approximately 2 percentage points in 2025.”

“Our principal competitors in the applied markets arena include: Danaher Corporation, PerkinElmer Inc., Shimadzu Corporation, Thermo Fisher Scientific Inc. and Waters Corporation.”

“Demand for some of our products and services depends on the capital spending policies of our customers, research and development budgets and on government funding policies.”

“Agilent is the world's leading provider of gas chromatographs, both laboratory and portable models.”

“due primarily to the overall pressures on our customers' capital expenditure spending which continued in 2024”

“After an extended period of constrained capital spending, many customers' ability to spend capital budgets has begun to normalize, with the exception of customers receiving funding from the U.S. federal government.”

“Currently, United States federal agencies are operating under a continuing resolution that is set to expire on January 30, 2026.”

“tariffs imposed by the United States on goods from other countries and tariffs imposed by other countries on U.S. goods, including tariffs and trade policies by the U.S. government on various imports from China and by the Chinese government on certain U.S. goods”

“While the recent tariff changes adversely impacted our costs of revenue beginning in the second half of fiscal year 2025, we expect to substantially mitigate the impact during our fiscal year 2026.”

“We are integrating artificial intelligence and machine learning technologies ("AI") into our business operations, products and services”

“If during a market downturn we had excess manufacturing capacity, then our fixed costs associated with excess manufacturing capacity would adversely affect our gross margins and operating results.”

“as we collaborate with pharmaceutical customers to develop drugs such as companion diagnostics assays or provide drug components like active pharmaceutical ingredients, we face risks that those drug programs may be cancelled upon clinical trial failures”

“we have consolidated, and may further consolidate, our manufacturing operations to certain of our facilities to achieve efficiencies and gross margin improvements”

“industries that are characterized by increased competition through frequent new product and service introductions, rapid technological changes and changing industry standards”